All About Multiple Sclerosis

More MS news articles for August 2003

Intravenous Liposomal Prednisolone Downregulates In Situ TNF-alpha Production by T-cells in Experimental Autoimmune Encephalomyelitis

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12923250&dopt=Abstract

J Histochem Cytochem. 2003 Sep;51(9):1241-4
Schmidt J, Metselaar JM, Gold R.
Department of Neurology, University of Wurzburg, Wurzburg, Germany.

Multiple sclerosis (MS) relapses are treated with high-dose IV glucocorticosteroids.

Here we investigated mechanisms of long-circulating polyethylene glycol-coated liposomes encapsulating prednisolone (PL) in adoptive transfer experimental autoimmune encephalomyelitis.

Rats received IV 10 mg/kg PL 6, 18, or 42 hr before sacrifice at disease maximum.

In formalin-fixed, paraffin-embedded spinal cord we employed a nonfluorescent immunohistochemical (IHC) double labeling.

We stained for tumor necrosis factor-alpha (TNF-alpha) in combination with a T-cell antigen.

Compared with PBS-containing liposomes, PL at 18 hr, and more at 42 hr, significantly reduced the rate of TNF-alpha double-labeled T-cells.

This correlated with an ameliorated disease score at day 5 after PL 42 hr.

Our results help to further understand mechanisms of action of drug targeting by liposomal steroids, with possible implications for treatment of autoimmune disorders such as MS.